A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | NCT04586231 | Trialant

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | NCT04586231 | Trialant

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Eligibility Criteria: Inclusion Criteria:

Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC).

Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose.

Measurable disease per RECIST 1.1 criteria as assessed by local study investigator.

Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization.

Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease

Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC.

A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib.

A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm.

Adequately controlled blood pressure.

Adequate organ function.

Exclusion Criteria:

A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen.

Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy.

Known central nervous system (CNS) metastases and/or carcinomatous meningitis.

Clinically significant cardiac disease within 6 months of first dose of study intervention.

Prolongation of QTc interval to >480 ms.

Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable.

Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.

Moderate to severe hepatic impairment.

History of significant bleeding within 3 months before randomization.

History of solid organ transplantation.

Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.

Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).

Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations.

Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization.

Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor.

Prior treatment with lenvatinib.

Prior treatment with cabozantinib.

Currently participating in a study of an investigational agent or using an investigational device.

Active infection requiring systemic therapy.

History of human immunodeficiency virus (HIV) infection.

History of hepatitis B or known active hepatitis C infection.

Ironwood Cancer & Research Centers ( Site 0077)

Chandler, Arizona 85224, United States

Cedars Sinai Medical Center ( Site 0027)

Los Angeles, California 90048, United States

UCLA Hematology/Oncology - Santa Monica ( Site 0048)

Los Angeles, California 90404, United States

St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)

Orange, California 92868, United States

University of California, Irvine ( Site 0029)

Orange, California 92868, United States

Providence Saint John's Health Center ( Site 0083)

Santa Monica, California 90404, United States

Georgetown University Medical Center ( Site 0006)

Washington D.C., District of Columbia 20007, United States

AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003)

Orlando, Florida 32804, United States

Orlando Health, Inc. ( Site 0035)

Orlando, Florida 32806, United States

University Cancer & Blood Center, LLC ( Site 0057)

Athens, Georgia 30607, United States

Emory University Hospital ( Site 0012)

Atlanta, Georgia 30322, United States

Rush University Medical Center ( Site 0040)

Chicago, Illinois 60607, United States

Illinois Cancer Care, PC ( Site 0008)

Peoria, Illinois 61615, United States

Parkview Cancer Institute ( Site 0088)

Fort Wayne, Indiana 46845, United States

Norton Cancer Institute - St. Matthews ( Site 0065)

Louisville, Kentucky 40207, United States

Tulane University School of Medicine ( Site 0098)

New Orleans, Louisiana 70112, United States

Lahey Hospital & Medical Center ( Site 0090)

Burlington, Massachusetts 01805, United States

Cancer & Hematology Centers of Western Michigan ( Site 0018)

Grand Rapids, Michigan 49503, United States

HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)

Saint Louis Park, Minnesota 55426, United States

University of Mississippi Medical Ctr ( Site 0037)

Jackson, Mississippi 39213, United States

Cancer Partners of Nebraska ( Site 0086)

Lincoln, Nebraska 68516, United States

Rutgers Cancer Institute of New Jersey ( Site 0078)

New Brunswick, New Jersey 08903, United States

R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)

Lake Success, New York 11042, United States

Memorial Sloan Kettering Cancer Center ( Site 0055)

New York, New York 10065, United States

Levine Cancer Institute ( Site 0004)

Charlotte, North Carolina 28204, United States

Duke Cancer Institute ( Site 0096)

Durham, North Carolina 27710, United States

Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)

Allentown, Pennsylvania 18103, United States

University of Texas, Southwestern Medical Center ( Site 0015)

Dallas, Texas 75235, United States

Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)

Salt Lake City, Utah 84112, United States

University of Vermont Medical Center ( Site 0001)

Burlington, Vermont 05401, United States

Blue Ridge Cancer Care - Roanoke ( Site 0043)

Roanoke, Virginia 24014, United States

Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)

Seattle, Washington 98109, United States

Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)

Wenatchee, Washington 98801, United States

Centro de Urología (CDU) ( Site 0803)

CABA, Buenos Aires C1120AAT, Argentina

Hospital Británico de Buenos Aires-Oncology ( Site 0801)

Ciudad Autónoma de Buenos Aires, Buenos Aires C1280AEB, Argentina

Instituto Alexander Fleming ( Site 0800)

Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina

Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)

Buenos Aires, Buenos Aires F.D. C1419AHN, Argentina

Sanatorio Británico-Clinical Oncology Department ( Site 0802)

Rosario, Santa Fe Province 2000, Argentina

Sanatorio Parque ( Site 0806)

Rosario, Santa Fe Province S2000DSV, Argentina

GenesisCare North Shore ( Site 4011)

St Leonards, New South Wales 2065, Australia

Lyell McEwin Hospital ( Site 4004)

Elizabeth Vale, South Australia 5112, Australia

Peninsula Health Frankston Hospital ( Site 4001)

Frankston, Victoria 3199, Australia

Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010)

Melbourne, Victoria 3000, Australia

Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)

Vienna, State of Vienna 1160, Austria

Medizinische Universitätsklinik Graz ( Site 1051)

Graz, Styria 8036, Austria

Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001)

Linz, Upper Austria 4020, Austria

Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)

Vienna, 1020, Austria

Medizinische Universität Wien ( Site 1021)

Vienna, 1090, Austria

Institut Jules Bordet ( Site 1103)

Anderlecht, Bruxelles-Capitale, Region de 1070, Belgium

Cliniques Universitaires Saint Luc - Bruxelles ( Site 1105)

Brussels, Bruxelles-Capitale, Region de 1200, Belgium

Grand Hopital de Charleroi ( Site 1104)

Gilly, Hainaut 6060, Belgium

UZ Gent ( Site 1100)

Ghent, Oost-Vlaanderen 9000, Belgium

UZ Leuven ( Site 1101)

Leuven, Vlaams-Brabant 3000, Belgium

CHU de Liege ( Site 1102)

Liège, 4000, Belgium

Liga Norte Riograndense Contra o Cancer ( Site 0313)

Natal, Rio Grande do Norte 59151600, Brazil

Centro Gaucho Integrado de Oncologia ( Site 0304)

Porto Alegre, Rio Grande do Sul 90110-270, Brazil

BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0311)

São Paulo, 01321-001, Brazil

Hospital Paulistano - Amil Clinical Research ( Site 0308)

São Paulo, 01321-001, Brazil

Arthur J.E. Child Comprehensive Cancer Centre ( Site 0109)

Calgary, Alberta T2N 5G2, Canada

Cross Cancer Institute ( Site 0111)

Edmonton, Alberta T6G 1Z2, Canada

BC Cancer Vancouver-Clinical Trials Unit ( Site 0110)

Vancouver, British Columbia V5Z 4E6, Canada

The Moncton Hospital ( Site 0101)

Moncton, New Brunswick E1C 6Z8, Canada

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114)

Hamilton, Ontario L8V 5C2, Canada

Kingston Health Sciences Centre ( Site 0105)

Kingston, Ontario K7L 2V7, Canada

The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116)

Ottawa, Ontario K1H 8L6, Canada

Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113)

Toronto, Ontario M4N 3M5, Canada

CISSS de la Monteregie-Centre ( Site 0103)

Greenfield Park, Quebec J4V 2H1, Canada

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0115)

Québec, Quebec G1J 1Z4, Canada

CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102)

Sherbrooke, Quebec J1H 5N4, Canada

James Lind Centro de Investigacion del Cancer ( Site 0402)

Temuco, Araucania 4800827, Chile

Bradfordhill-Clinical Area ( Site 0400)

Santiago, Region M. de Santiago 8420383, Chile

Fundacion Colombiana de Cancerología Clinica Vida ( Site 0505)

Medellín, Antioquia 050030, Colombia

Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508)

Valledupar, Cesar Department 200001, Colombia

Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500)

Bogotá, Cundinamarca 111511, Colombia

Fundación Cardiovascular de Colombia ( Site 0501)

Piedecuesta, Santander Department 681017, Colombia

Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203)

Brno, Brno-mesto 656 53, Czechia

Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200)

Prague, Praha 4 140 59, Czechia

Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 2205)

Prague, Praha 5 150 06, Czechia

Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 2204)

České Budějovice, South Bohemian Region 37001, Czechia

Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201)

Hradec Králové, 500 05, Czechia

Tampereen yliopistollinen sairaala ( Site 1801)

Tampere, Pirkanmaa 33520, Finland

TYKS ( Site 1802)

Turku, Southwest Finland 20520, Finland

HYKS ( Site 1800)

Helsinki, Uusimaa 00290, Finland

Institut Jean Godinot ( Site 1216)

Reims, Ain 51726, France

Centre Antoine Lacassagne ( Site 1217)

Nice, Alpes-Maritimes 06189, France

Hopitaux Universitaires de Strasbourg- Hopital de Hautepierre ( Site 1218)

Strasbourg, Bas-Rhin 67200, France

CHU de Bordeaux- Hopital Saint Andre ( Site 1209)

Bordeaux, Gironde 33000, France

Institut Claudius Regaud ( Site 1215)

Toulouse, Haute-Garonne 31059, France

Clinique Francois Chenieux ( Site 1210)

Limoges, Haute-Vienne 87039, France

Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201)

Saint-Herblain, Loire-Atlantique 44805, France

Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)

Angers, Maine-et-Loire 49055, France

Hopital Tenon ( Site 1213)

Paris, 75020, France

Klinik fuer Urologie ( Site 1303)

Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany

NCT-Department of Medical Oncology ( Site 1320)

Heidelberg, Baden-Wurttemberg 69120, Germany

Klinikum Nuernberg Nord ( Site 1300)

Nuremberg, Bavaria 90419, Germany

Universitaetsklinikum Frankfurt ( Site 1301)

Frankfurt am Main, Hesse 60590, Germany

Universitaetsklinikum Aachen AOER ( Site 1317)

Aachen, North Rhine-Westphalia 52074, Germany

Universitaetsklinikum des Saarlandes ( Site 1305)

Homburg/ Saar, Saarland 66421, Germany

Krankenhaus Martha Maria Halle-Doelau ( Site 1314)

Halle, Saxony-Anhalt 06120, Germany

Helios Klinikum Erfurt GmbH ( Site 1315)

Erfurt, Thuringia 99089, Germany

Charite Universitaetsmedizin Berlin ( Site 1321)

Berlin, 10117, Germany

HELIOS Klinikum Berlin-Buch ( Site 1311)

Berlin, 13125, Germany

UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302)

Pátrai, Achaia 26504, Greece

Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304)

Athens, Attica 115 28, Greece

Athens Medical Center ( Site 3303)

Athens, Attica 151 25, Greece

ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 3301)

Chaïdári, Attica 124 62, Greece

European Interbalkan Medical Center-Oncology Department ( Site 3300)

Thessaloniki, 570 01, Greece

Mater Misericordiae University Hospital ( Site 3201)

Dublin, D07 R2WY, Ireland

Mater Private Hospital - Dublin ( Site 3202)

Dublin, D07 R2WY, Ireland

Tallaght University Hospital ( Site 3200)

Dublin, D24NR0A, Ireland

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407)

Meldola, Forli-Cesena 47014, Italy

Istituto Clinico Humanitas Research Hospital ( Site 1406)

Rozzano, Milano 20089, Italy

Ospedale San Luigi Gonzaga ( Site 1405)

Orbassano, Torino 10043, Italy

Medical Oncology Ospedale San Donato ( Site 1404)

Arezzo, 52100, Italy

Azienda Ospedaliera Policlinico di Bari ( Site 1402)

Bari, 70124, Italy

IRCCS Ospedale San Raffaele ( Site 1409)

Milan, 20132, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400)

Milan, 20133, Italy

Istituti Clinici Scientifici Maugeri Spa ( Site 1403)

Pavia, 27100, Italy

Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410)

Roma, 00168, Italy

Azienda Ospedaliera S. Maria di Terni ( Site 1401)

Terni, 05100, Italy

Ospedale Maggiore Borgo Trento ( Site 1408)

Verona, 37126, Italy

Fujita Health University Hospital ( Site 5003)

Toyoake, Aichi-ken 470-1192, Japan

National Cancer Center Hospital East ( Site 5000)

Kashiwa, Chiba 2778577, Japan

Toho University Sakura Medical Center ( Site 5014)

Sakura, Chiba 285-8741, Japan

Sapporo Medical University Hospital ( Site 5008)

Sapporo, Hokkaido 060-8543, Japan

Kobe City Medical Center General Hospital ( Site 5017)

Kobe, Hyōgo 650-0047, Japan

Yokohama City University Hospital ( Site 5007)

Yokohama, Kanagawa 236-0004, Japan

Nara Medical University Hospital ( Site 5002)

Kashihara, Nara 634-0813, Japan

Kindai University Hospital ( Site 5010)

Sakai, Osaka 590-0197, Japan

The University of Osaka Hospital ( Site 5012)

Suita, Osaka 565-0871, Japan

Hamamatsu University Hospital ( Site 5004)

Hamamatsu, Shizuoka 431-3192, Japan

Institute of Science Tokyo Hospital ( Site 5009)

Bunkyo-ku, Tokyo 113-8510, Japan

Toranomon Hospital ( Site 5001)

Minato-ku, Tokyo 105-8470, Japan

Kyushu University Hospital ( Site 5005)

Fukuoka, 812-8582, Japan

Niigata University Medical & Dental Hospital ( Site 5013)

Niigata, 951-8520, Japan

Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5016)

Osaka, 541-8567, Japan

Nippon Medical School Hospital ( Site 5006)

Tokyo, 113-8603, Japan

Tokyo Women's Medical University Adachi Medical Center ( Site 5015)

Tokyo, 123-8558, Japan

Keio University Hospital ( Site 5011)

Tokyo, 160-8582, Japan

Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)

Sittard-Geleen, Limburg 6162 BG, Netherlands

Amphia Hospital Location Molengracht ( Site 1912)

Breda, North Brabant 4818 CK, Netherlands

Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)

Amsterdam, North Holland 1066 CX, Netherlands

Medisch Centrum Leeuwarden ( Site 1905)

Leeuwarden, Provincie Friesland 8934 AD, Netherlands

Erasmus MC ( Site 1913)

Rotterdam, South Holland 3015 GD, Netherlands

Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909)

Schiedam, South Holland 3118 JH, Netherlands

Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1917)

The Hague, South Holland 2545 AA, Netherlands

Universitair Medisch Centrum Utrecht ( Site 1910)

Utrecht, 3584 CX, Netherlands

Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2401)

Poznan, Greater Poland Voivodeship 60-569, Poland

Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402)

Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 2403)

Krakow, Lesser Poland Voivodeship 31-115, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)

Warsaw, Masovian Voivodeship 02-781, Poland

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2500)

Cluj-Napoca, Cluj 400015, Romania

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2501)

Cluj-Napoca, Cluj 400015, Romania

Centrul de Oncologie "Sfântul Nectarie" ( Site 2502)

Craiova, Dolj 200542, Romania

Ivanovo Regional Oncology Dispensary ( Site 2616)

Ivanovo, Ivanovo Oblast 153040, Russia

FSBI United Hospital with Polyclinic ( Site 2613)

Moscow, Moscow 119285, Russia

SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)

Moscow, Moscow 125130, Russia

MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)

Krasnogorsk, Moscow Oblast 143442, Russia

Hadassah Medical-Oncology department ( Site 2609)

Moscow, Moscow Oblast 121205, Russia

Volgograd Regional Uronephrological Center ( Site 2615)

Volzhsky, Volgograd Oblast 404120, Russia

Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)

Yaroslavl, Yaroslavl Oblast 150054, Russia

Chonnam National University Hwasun Hospital-Oncology ( Site 4203)

Hwasun, Jeonranamdo 58128, South Korea

Asan Medical Center ( Site 4200)

Seoul, 05505, South Korea

Samsung Medical Center ( Site 4201)

Seoul, 06351, South Korea

Complejo Hospitalario Universitario A Coruna ( Site 1502)

A Coruña, La Coruna 15006, Spain

Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508)

Madrid, Madrid, Comunidad de 28041, Spain

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)

Barcelona, 08035, Spain

Hospital Clinic i Provincial ( Site 1500)

Barcelona, 08036, Spain

Hospital Santa Creu i Sant Pau ( Site 1501)

Barcelona, 08041, Spain

Hospital General Universitario Gregorio Maranon ( Site 1505)

Madrid, 28009, Spain

Hospital Clinico San Carlos... ( Site 1504)

Madrid, 28040, Spain

Hospital Virgen del Rocio ( Site 1503)

Seville, 41013, Spain

Hopitaux Universitaires de Geneve HUG ( Site 1602)

Geneva, Canton of Geneva 1211, Switzerland

Universitaetsspital Zuerich ( Site 1601)

Zurich, Canton of Zurich 8001, Switzerland

Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)

Bellinzona, Canton Ticino 6500, Switzerland

Kantonsspital Graubuenden ( Site 1600)

Chur, Kanton Graubünden 7000, Switzerland

Aberdeen Royal Infirmary-Department of Oncology ( Site 3105)

Aberdeen, Aberdeen City AB25 2ZN, United Kingdom

Royal United Hospital Bath England ( Site 3108)

Bath, Bath And North East Somerset BA1 3NG, United Kingdom

Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106)

Nottingham, England NG5 1PF, United Kingdom

Southend University Hospital ( Site 3112)

Southend, Essex SS0 0RY, United Kingdom

Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107)

London, London, City of W6 8RF, United Kingdom

Mount Vernon Cancer Centre ( Site 3101)

Northwood, London, City of HA6 2RN, United Kingdom

Musgrove Park Hospital ( Site 3103)

Taunton, Somerset TA1 5DA, United Kingdom

Singleton Hospital ( Site 3111)

Swansea, Wales SA2 8QA, United Kingdom